The secret melanoma switch: the discovery that could revolutionise treatment

Turning it off could therefore provide one of the most effective strategies against the most aggressive of skin cancers

by Maria Rita Montebelli

5 May 2026

3' min read

Translated by AI

Versione italiana

Key points

The double play of melanoma
The invisible wall that makes cancer impenetrable
A new strategy on the horizon: hitting the tumour on two fronts
A discovery that could also affect other cancers
Why this research is important

3' min read

Translated by AI

Versione italiana

There is a 'switch', codenamed HOXD13, hidden inside melanoma cells. When it turns on, it accelerates tumour growth and, at the same time, 'puts the immune system to sleep'. Switching it off could therefore provide one of the most effective strategies against the most aggressive of skin cancers. Giving the news, through a study published in Cancer Discovery, is a team from NYU Langone Health.

The double game of melanoma

HOXD13 belongs to the family of 'transcription factors', molecules that control which genes should be switched on or off in our DNA. Basically, they are like conductors of the cell's orchestra. In melanoma, however, HOXD13 plays dangerous music.

When activated, on the one hand, it accelerates tumour growth by stimulating angiogenesis, i.e. the formation of new blood vessels, which carry more oxygen and nutrients, thus providing vital fuel for cancer cells. But that's not all. HOXD13 helps the tumour hide by reducing the activity of cytotoxic T lymphocytes, i.e. immune system cells specialised in recognising and destroying tumours. These immune system cells are a kind of sentinels engaged in a continuous patrol to promptly detect and neutralise threats. In patients with high levels of this protein, T lymphocytes are less numerous and have more difficulty penetrating the tumour. And the two actions put together mean that the melanoma grows faster and defends itself better against attacks from our immune system.

The invisible wall that makes the tumour impenetrable

The most interesting discovery made by the American researchers concerns the way HOXD13 manages to create a kind of protective barrier around the tumour.

The protein increases levels of a molecule called CD73, which in turn produces adenosine. This substance works as a 'sedative' for the immune system: it slows down the T lymphocytes and prevents them from attacking the tumour cells. It is as if the tumour is building an invisible chemical barrier around itself.

But there is good news. The authors of the research managed to 'switch off' HOXD13 in the laboratory; this produced two consequences: the tumours shrank in volume and the T lymphocytes returned to the attack.

A new strategy on the horizon: targeting cancer on two fronts

This discovery opens the door to a double-sided, more sophisticated and effective therapeutic approach: blocking tumour growth and reactivating the immune system in one fell swoop.

A number of combination therapeutic strategies already in clinical trials target precisely these mechanisms; these are VEGF pathway inhibitors (which reduce angiogenesis) or drugs that block adenosine receptors, combined with immunotherapy.

The idea now is to combine all these approaches, especially in patients with high HOXD13 levels, to achieve a 'double hit' effect.

A discovery that could also affect other tumours

The work was carried out on over 200 melanoma patient samples from the United States, Brazil and Mexico and was accompanied by a series of experiments on animal models and human melanoma cells.

But this mechanism, studied in melanoma, could also apply to other neoplasms. Scientists are already investigating whether HOXD13 also plays the same role in other aggressive tumours, such as in certain brain tumours (glioblastomas) and sarcomas.

Why this research is important

Melanoma is known for its ability to adapt and resist treatment. This is why the discovery of a master switch that controls both tumour growth and its ability to escape the immune system is so valuable. We are not yet at the definitive cure for melanoma, but the discovery of the key role of HOXD13 could pave the way for more targeted and personalised treatments.